OBJECTIVE: To determine rate of and risk factors for birth defects in infants born to HIV-infected women receivingnucleoside and protease inhibitor antiretroviral (ARV) therapy. METHODS:Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission. Maternal therapy was categorized by trimester of earliest exposure. Birth defects were coded using conventions of the Antiretroviral Pregnancy Registry. RESULTS:Birth defects were detected in 60/1414 (4.2%; 95% CI 3.3-5.4%) infants including 30/636 (4.7%; 95% CI 3.2-6.7%) with first trimester ARV exposure and 30/778 (3.9%; 95% CI 2.6-5.5%) with exposure only after the first trimester (P=0.51). Rates of classes of defects were similar between first trimester compared to later exposure groups except heart defects which occurred in 16 (2.5%; 95% CI 1.4-4.1%) with first trimester ARV exposure and in six (0.8%; 95% CI 0.3-1.7%) infants with later exposure (P=0.02). Exposure to ARV was not associated with specific types of heart defects. Two cases of cardiomyopathy were noted. CONCLUSION: ARV use in early pregnancy was not associated with an increased risk of birth defects overall. The possible association of ARV exposure with heart defects requires further surveillance.
RCT Entities:
OBJECTIVE: To determine rate of and risk factors for birth defects in infantsborn to HIV-infectedwomen receiving nucleoside and protease inhibitor antiretroviral (ARV) therapy. METHODS:Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission. Maternal therapy was categorized by trimester of earliest exposure. Birth defects were coded using conventions of the Antiretroviral Pregnancy Registry. RESULTS:Birth defects were detected in 60/1414 (4.2%; 95% CI 3.3-5.4%) infants including 30/636 (4.7%; 95% CI 3.2-6.7%) with first trimester ARV exposure and 30/778 (3.9%; 95% CI 2.6-5.5%) with exposure only after the first trimester (P=0.51). Rates of classes of defects were similar between first trimester compared to later exposure groups except heart defects which occurred in 16 (2.5%; 95% CI 1.4-4.1%) with first trimester ARV exposure and in six (0.8%; 95% CI 0.3-1.7%) infants with later exposure (P=0.02). Exposure to ARV was not associated with specific types of heart defects. Two cases of cardiomyopathy were noted. CONCLUSION: ARV use in early pregnancy was not associated with an increased risk of birth defects overall. The possible association of ARV exposure with heart defects requires further surveillance.
Authors: M Gerschenson; S W Erhart; C Y Paik; M C St Claire; K Nagashima; B Skopets; S W Harbaugh; J W Harbaugh; W Quan; M C Poirier Journal: AIDS Res Hum Retroviruses Date: 2000-05-01 Impact factor: 2.205
Authors: Stacy D Fisher; Kirk A Easley; E John Orav; Steven D Colan; Samuel Kaplan; Thomas J Starc; J Timothy Bricker; Wyman W Lai; Douglas S Moodie; George Sopko; Steven E Lipshultz Journal: Am Heart J Date: 2005-09 Impact factor: 4.749
Authors: R S Sperling; D E Shapiro; G D McSherry; P Britto; B E Cunningham; M Culnane; R W Coombs; G Scott; R B Van Dyke; W T Shearer; E Jimenez; C Diaz; D D Harrison; J F Delfraissy Journal: AIDS Date: 1998-10-01 Impact factor: 4.177
Authors: Claire L Townsend; Barbara A Willey; Mario Cortina-Borja; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Kelesitse Phiri; Sonia Hernandez-Diaz; Kate B Dugan; Paige L Williams; Judith A Dudley; Astride Jules; S Todd Callahan; George R Seage; William O Cooper Journal: Pediatr Infect Dis J Date: 2014-07 Impact factor: 2.129
Authors: Kathryn Rough; Jenny W Sun; George R Seage; Paige L Williams; Krista F Huybrechts; Brian T Bateman; Sonia Hernandez-Diaz Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Paige L Williams; Marilyn J Crain; Cenk Yildirim; Rohan Hazra; Russell B Van Dyke; Kenneth Rich; Jennifer S Read; Emma Stuard; Mobeen Rathore; Hermann A Mendez; D Heather Watts Journal: JAMA Pediatr Date: 2015-01 Impact factor: 16.193
Authors: Maria F M Barral; Gisele R de Oliveira; Rubens C Lobato; Raul A Mendoza-Sassi; Ana M B Martínez; Carla V Gonçalves Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Mar-Apr Impact factor: 1.846